bringing health insight

Treat the
Untreatable

       

Our pipeline of novel therapies, which is built on our RBP4 (Retinol Binding Protein 4) IP Portfolio, is focused on meeting the unmet needs of patients suffering from blindness, liver disease and diabetes.

 Novel Therapy for

Unmet Medical Need

Belite Bio™ is a San Diego based clinical stage biopharmaceutical drug development company targeting untreatable eye diseases, such as atrophic age-related macular degeneration (commonly known as dry AMD) and Stargardt disease, and metabolic diseases.

Developed from our RBP4 intellectual property portfolio, our lead candidate, LBS-008, has initiated its phase 3 for Stargardt disease, an inherited juvenile form of macular degeneration, and expects to initiate its phase 3 for dry age-related macular degeneration in 2022. LBS-008 has obtained Orphan Drug Designation in the United States and Europe and has been granted a Rare Pediatric Disease (RPD) designation and Fast Track Designation in the US.


Meet the team

LBS 008

Bringing Hope to

Incurable Blindness

Dry AMD / Stargardt Disease

Phase 3

Details

LBS 009

Blocking the Path to

Metabolic disease

Non-Fatty Liver Disease / Type 2 Diabetes

Preclinical

Details

Our Technology

RBP4 intellectual property portfolio

The RBP4 antagonists developed from our RBP4 intellectual property portfolio effectively reduces circulating levels of RBP4, a vitamin A transporter protein linked to the development of aging metabolic diseases, including dry age-related macular degeneration, liver disease and diabetes.

View Presentation

Patient Registry

病患信息表

Contact

Join our mailing list.


Sign up to receive important updates and news from Belite Bio